Clinical Trial Update: Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating moclobemide as an adjunct to nicotine replacement therapy in female smokers. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• Moclobemide (moclobemide)

Snippet

Sponsor: Jed E. Rose | Conditions: Nicotine Dependence | Phase 2 | Status: COMPLETED | Results posted: 2015-07-29